A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00707538
Recruitment Status : Completed
First Posted : July 1, 2008
Last Update Posted : August 18, 2011
Information provided by:
Lantheus Medical Imaging

Brief Summary:
The purpose of this clinical research study is to learn the biodistribution of injection of BMS747158 at stress and assess the safety of two doses of BMS747158

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: BMS747158 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase I Dosimetry, Biodistribution and Safety Study of BMS747158 in Healthy Subjects Undergoing 2-Day Rest/Stress Positron Emission Tomography
Study Start Date : June 2008
Actual Primary Completion Date : October 2008
Actual Study Completion Date : October 2008

Arm Intervention/treatment
Experimental: 1 Drug: BMS747158
2 IV injection of ~11 mCi (total) F-18 labeled compound

Primary Outcome Measures :
  1. Dosimetry analysis following whole body imaging after stress injection [ Time Frame: Imaging takes place approximately 0 - 300 minutes post injection ]

Secondary Outcome Measures :
  1. Safety analysis following vital signs, ECGs, EEG, neuro and physical exams, telephone and visit follow up, and blood draws for chemistry and hematology post injection of BMS747158 at rest and stress [ Time Frame: Screening (14 days prior to dosing) through 14 days post dose administration ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • age 18-40
  • BMI 18-30 kg/m2
  • No active or chronic illnesses
  • If female: not pregnant, use of birth control or not of child-bearing potential

Exclusion Criteria:

  • Significant active or chronic illness
  • Any neurological disorder
  • GI disease within 3 months
  • Recent infection
  • Major surgery within 4 weeks
  • Donation of blood within 4 weeks
  • Blood transfusion within 4 weeks
  • Recent history drug/alcohol abuse
  • Head trauma
  • Significant screening ECG, EEG, lab tests, physical exam and vital signs abnormalities
  • Prescription or OTC drugs within 2 weeks
  • Exposure to any other investigational

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00707538

United States, California
UCLA Medical Center
Los Angeles, California, United States, 90095
United States, Maryland
John Hopkins University
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Lantheus Medical Imaging
Principal Investigator: Jamshid Maddahi, MD University of California, Los Angeles

Responsible Party: Dana Washburn, MD, Lantheus Medical Imaging Identifier: NCT00707538     History of Changes
Other Study ID Numbers: BMS747158-102
First Posted: July 1, 2008    Key Record Dates
Last Update Posted: August 18, 2011
Last Verified: August 2011